Morgan Stanley on United Therapeutics Corp. (UTHR): project Tyvaso '2030/2035 risk-adjusted sales in IPF of $1.2bn/$2.5bn'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
United Therapeutics Corp. (UTHR) PT Raised to $733 at Jefferies
March 30, 2026 10:26 AM EDTJefferies analyst Roger Song raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $733.00 (from $668.00) while maintaining a Buy rating.
The analyst comments "Bottom line. Topline of 2nd Tyvaso Ph3 study for IPF, TETON-1 (US/ Canada) exceeded investors/ our expectations, even better than... More
United Therapeutics Corp. (UTHR) PT Raised to $660 at TD Cowen, 'remains a top pick'
March 30, 2026 8:33 AM EDTTD Cowen analyst Joseph Thome raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $660.00 (from $575.00) while maintaining a Buy rating.
The analyst comments "UTHR announced that the second Ph. III study of Tyvaso for IPF (TETON-1) hit the primary... More
